Cardiovascular risk in patients with treated familial hypercholesterolaemia and patients with severe hypertriglyceridaemia Sir, Dr Way and colleagues' important paper (July 1986 JRSM, p 391)suggests that hypertriglyceridaemia is an appreciable cardiovascular risk. Their study reinforces the findings of an equally elegant earlier study which reported a 'hypercoagulable' state in association with hypertriglyceridaemia 1 • However, Way et al. did not assess the coagulation factors which were included in the earlier study". This detail would have helped establish whether any association between hypertriglyceridaemia and ischaemic heart disease (IHD) is mainly mediated by concomitant unfavourable changes in coagulation factors.
We are especially interested in this question because of the association of diabetes mellitus with hypertriglyceridaemia 2 and raised levels of plasma coagulation factors including fibrinogen", Furthermore, the study by Way et al. suggests that patients with hypertriglyceridaemia alone should be treated and there is now evidence that bezafibrate, which lowers both plasma cholesterol and triglyceride concentrations, also causes a significant fall in plasma fibrinogen concentrations". This recent observation is clinically relevant because plasma fibrinogen is a powerful predictor of IHD 1 • 3 • s, a finding that is in agreement with the central role that this coagulation factor plays in coagulation, plasma viscosity and platelet functions. We are unaware if treatment of hypercholesterolaemia with cholestyramine also significantly reduces plasma fibrinogen.
There is further evidence linking lipid metabolism with plasma fibrinogen levels since elevated plasma non-esterified fatty acid (NEF A) concentrations stimulate fibrinogen synthesis". This observation could therefore account, at least in part, for the elevated plasma fibrinogen levels reported in diabetics since they tend to have elevated plasma NEFA levels 2 • 7 • Did the hypertriglyceridaemic patients described by Way et al. also have raised plasma NEFA levels? Unfortunately, although we have documented that supplementation with dihomogammalinolenic acid lowers plasma NEF A levels in diabetics, we did not establish whether plasma fibrinogen concentrations were also decreased.
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Finally, previous studies investigating the incidence oflHD in association with hypertriglyceridaemia may not have shown a convincing link (as discussed by Way et al. and in reference 1) because coagulation factors are possibly not invariably raised in hypertriglyceridaemia. Other factors such as diet, race, stress, control of lipolysis, and severity ofhypertriglyceridaemia I may also be relevant. 1986;3:7-12 Intestinal malformations and Down's syndrome in Arabs
D P
Sir, We would like to report our 7-year-experience (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) of the different intestinal malformations seen in the first 600 consecutive Down's syndrome (DS) neonates and infants (mostly Arab) to be diagnosed clinically and cytogenetically by trypsin-G banding techniques in Kuwait. Seventeen patients (11males, 6 females) had associated intestinal malformations (2.8%) and underwent operation. Seven cases (1.16%) had imperforate anus, 6 (1%) duodenal obstruction and 4 (0.67%) Hirschprung's disease. Sixteen DS patients had regular trisomy 21. One case with DS phenotype died before karyotyping but her mother proved to be a balanced translocation carrier with 46XX,t(14q;21q) karyotype.
In a previous study of congenital malformations in Kuwaiti, no mention was made of any association between gut malformations and DS. This study estimated separately the incidence of gut anomalies and DS to be 1.9/1000 and 1.1/1000 births respectively. Only 20 DS patients were included in this study.
The association of different gastrointestinal malformations has been well known for some time.
